Login
Sangamo Therapeutics NASDAQ: SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies
| Name | Sangamo Therapeutics |
| Ticker | SGMO |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
|
Price
52W Low/High |
9.94
9.23 / 18.18 |
| Momentum | Weak Down |
| Market cap | 1.4 B |
| 1Y Total Return |
-7.53 %
Subpar |
| 1Y Volatility |
76.19 %
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies
Details
| Ticker | SGMO |
| Name | Sangamo Therapeutics |
| ISIN | US8006771062 |
| CUSIP | 800677106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 07/23/2021
| Close Price | 9.94 |
| 52W Low/High | 9.23 / 18.18 |
| Market cap | 1.4 B |
| 1Y Total Return |
-7.53 %
Subpar |
| 1Y Volatility |
76.19 %
High Risk |
| Beta | 1.58 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -94.4 % |
| Cash from Op. / Cur. Liabilities | 0.90 |
| Diluted Earnings / Share | -0.88 |
| ROE | - |
| ROIC | -23.5 % |
| Price / Revenue | 10.8 |
| Price / Book | 3.0 |
| Price / CF | 11.8 |
| Current Ratio | 4.6 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to March
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
131
|
107
|
80
|
46
|
19
|
30
|
|
| Gross Profit |
131
|
107
|
80
|
46
|
19
|
30
|
|
| R&D |
196
|
153
|
126
|
76
|
63
|
67
|
|
| EBITDA |
-109
|
-85
|
-87
|
-56
|
-71
|
-56
|
|
| Operating Income |
-131
|
-106
|
-100
|
-61
|
-73
|
-57
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
143
|
116
|
102
|
86
|
71
|
70
|
|
| EPS exc. Extra |
-0.88
|
-0.82
|
-0.89
|
-0.70
|
-1.02
|
-0.73
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
877
|
584
|
543
|
281
|
147
|
197
|
|
| Cash, Eq & Invt ShortTerm |
589
|
358
|
351
|
230
|
129
|
188
|
|
| Total Current Assets |
607
|
371
|
363
|
236
|
134
|
191
|
|
| Total Non-Current Assets |
270
|
213
|
180
|
45
|
13
|
6
|
|
| Intangibles |
97
|
91
|
92
|
2
|
2
|
2
|
|
| Total Liabilities |
408
|
190
|
214
|
99
|
21
|
18
|
|
| Total Current Liabilities |
133
|
62
|
91
|
49
|
13
|
10
|
|
| Long Term Debt |
275
|
128
|
122
|
49
|
8
|
8
|
|
| Shareholder equity |
470
|
394
|
328
|
182
|
126
|
179
|
|
| Cash Flow | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
120
|
-118
|
10
|
6
|
-59
|
-52
|
|
| Depreciation |
14
|
11
|
3
|
2
|
1
|
1
|
|
| Cash from Investing |
-250
|
-21
|
-181
|
-95
|
40
|
43
|
|
| Capex |
19
|
18
|
46
|
6
|
1
|
1
|
|
| Cash from Financing |
168
|
142
|
221
|
105
|
4
|
17
|
|
| Stock Issued |
171
|
143
|
222
|
105
|
4
|
4
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-255
|
-140
|
-173
|
-121
|
-23
|
-31
|
|
| Ratios | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
4.6
|
6.0
|
4.0
|
4.8
|
10.2
|
18.9
|
|
| Financial Leverage D/E |
0.08
|
0.10
|
0.04
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-23.5 %
|
-23.8 %
|
-31.6 %
|
-36.7 %
|
-53.3 %
|
-26.2 %
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available